Anaplastic Lymphoma Kinase (ALK) Rearrangement-positive Lung Cancer with Transformation to Pleomorphic Carcinoma

Access this Article

Search this Article

Author(s)

    • Kamide Yosuke
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Oyama Tetsunari
    • Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Gunma University Hospital, Japan
    • Yamada Masanobu
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Kaira Kyoichi
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Watanabe Takuya
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Kuribayashi Shiko
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Ozawa Atsushi
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Koga Yasuhiko
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Ono Akihiro
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Sunaga Noriaki
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan
    • Hisada Takeshi
    • Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan

Abstract

A 55-year-old woman was diagnosed with a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) rearrangement-positive lung adenocarcinoma and treated with chemotherapy consisting of crizotinib, a tyrosine kinase inhibitor of ALK, as second-line chemotherapy. However, the size of the metastatic adrenal lesion increased, and the patient died due to multiple organ failure. An autopsy report revealed that the metastatic lesion of the adrenal tumor was ALK rearrangement-positive pleomorphic carcinoma. The epithelial-mesenchymal transition (EMT) marker vimentin was immunohistochemically positive in both the lung and adrenal lesions. The present case report suggests the possibility of transformation into pleomorphic carcinoma as a result of EMT in patients with ALK rearrangement-positive lung cancer.<br>

Journal

  • Internal Medicine

    Internal Medicine 54(22), 2905-2909, 2015

    The Japanese Society of Internal Medicine

Codes

Page Top